J Cancer 2016; 7(2):192-199. doi:10.7150/jca.13414
Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis
1. National Engineering Laboratory for Rice and Byproduct Deep Processing, Central South University of Forestry and Technology, Changsha, Hunan 410004, China;
2. Medical College, Hunan Normal University, Changsha, Hunan 410013, China;
3. College of Biology, Hunan University, Changsha, Hunan 410082, China.
4. Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA
* These authors contributed equally to this work.
Yang T, Yao H, He G, Song L, Liu N, Wang Y, Yang Y, Keller ET, Deng X. Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis. J Cancer 2016; 7(2):192-199. doi:10.7150/jca.13414. Available from http://www.jcancer.org/v07p0192.htm
Despite the tremendous improvement in cancer therapeutics, treatment of late-stage breast cancer remains a challenge for both basic scientists and clinicians. Lovastatin, a natural product derived from Aspergillus terreus or Monascus ruber, has been widely used as cholesterol-lowing drug in the clinic. It also has anti-cancer properties through poorly defined molecular mechanisms. In the present study, we employed a novel antibody microarray technology to investigate the molecular mechanisms through which lovastatin inhibits breast cancer. We found that lovastatin up-regulated 17 proteins and down-regulated 20 proteins in MDA-MB-231 breast cancer cells. These included proteins that modulate apoptosis, cell proliferation, differentiation, signal transduction, epithelial-to-mesenchymal transition and tumor metastasis. Modulation of these pathways may mediate, in part, the inhibitory activity of lovastatin on breast cancer.
Keywords: Natural products, Lovastatin, Breast cancer, Antibody microarray, Hypoxia